The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
第一作者:
Eoghan M,McCarthy
第一单位:
The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust.
作者:
医学主题词
英格兰(England);人类(Humans);免疫抑制剂(Immunosuppressive Agents);红斑狼疮, 系统性(Lupus Erythematosus, Systemic);诊疗准则(主题)(Practice Guidelines as Topic);威尔士(Wales)
DOI
10.1093/rheumatology/kex044
PMID
28431104
发布时间
2025-05-30
基金项目
WT_/Wellcome Trust/United Kingdom
CS-2013-13-032/DH_/Department of Health/United Kingdom
MR/M01665X/1/MRC_/Medical Research Council/United Kingdom
- 浏览11
Rheumatology (Oxford, England)
1041-1043页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



